Global Impetigo Treatment Market 2019-2023
- November 2018 •
- 104 pages •
- Report ID: 5658013 •
- Format: PDF
The evolving resistance of microorganisms is likely to push growth in the market. There has been evolving resistance owing to the frequent usage of oral antibiotics. Hence manufacturers are developing more effective antibiotics to treat skin infections. Technavio’s analysts have predicted that the impetigo treatment market will register a CAGR of about 7% by 2023.
Low cost of treatment
Impetigo is a common, highly contagious bacterial skin infection. However, the infection can be treated easily without spending much.
Side effects of drugs
Impetigo is a bacterial infection of the skin which is treated with topical antibiotics or oral drugs. However, few side effects of these drugs may pose a challenge to the market.
For the detailed list of factors that will drive and challenge the growth of the impetigo treatment market during the 2019-2023, view our report.
The market appears to be fragmented and with the presence of several companies including Cutanea Life Sciences and GlaxoSmithKline the competitive environment is quite intense. Factors such as the low cost of treatment and the low cost of treatment, will provide considerable growth opportunities to impetigo treatment manufactures. Cutanea Life Sciences, GlaxoSmithKline, LEO Pharma, and Medimetriks Pharmaceuticals are some of the major companies covered in this report.
‘With the presence of a considerable number of companies, this market appears to be fragmented. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market’s competitive landscape and offering information on the products offered by companies.’